Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05784441 · ClinicalTrials.gov registry record · Phase 1

A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL)

A Phase 1 study of Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, sponsored by Janssen Research & Development.

Active
Registry status
Phase 1
Development phase
21
Enrollment target
15
Study locations

NCT05784441: Active Phase 1 study of Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, sponsored by Janssen Research & Development.

NCT05784441 is a Phase 1 study of Relapsed or Refractory B Cell Non-Hodgkin Lymphoma that is active but no longer recruiting, run by Janssen Research & Development. The registered enrollment target is 21 participants, below the 27-participant average among 3 other Relapsed or Refractory B Cell Non-Hodgkin Lymphoma trials with a reported enrollment target (22% lower). The trial reports 15 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05784441, a Phase 1 study of Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, is active but no longer recruiting, sponsored by Janssen Research & Development.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
21 participants
Enrollment target
15
Study locations

Study Summary

The goal of this multicenter study is to test JNJ-90009530 in Relapsed or Refractory Non-Hodgkin Lymphoma Patients. The main questions the study aims to answer are: * can a dose of JNJ-90009530 be determined that is safe and well tolerated by patients. * will JNJ-90009530 help patients achieve a response and for how long?

Primary Outcome

The safety and tolerability will be measured by recording the occurence and severity of all adverse events or dose limiting toxicities that occur according to Common Terminology Criteria for Adverse Events (CTCAE) criteria version 5.0

Conditions Studied

Relapsed or Refractory B Cell Non-Hodgkin Lymphoma

Interventions

  • DRUG JNJ-90009530

Study Locations (15)

Other

  • Royal Prince Alfred Hospital - Camperdown
  • Monash Medical Centre - Clayton
  • Austin Hospital - Heidelberg
  • Royal Brisbane and Women's Hospital - Herston
  • Westmead Hospital - Westmead
  • Hadassah Medical Center - Jerusalem
  • Sheba Medical Center - Ramat Gan
  • University College London Hospitals - London

Iowa

  • University of Iowa Hospital - Iowa City

Kentucky

  • University of Kentucky - Lexington

Minnesota

  • Mayo Clinic Rochester - Rochester

New Jersey

  • Rutgers University - New Brunswick

Ohio

  • University Hospitals Cleveland Medical Center - Cleveland

Pennsylvania

  • University of Pennsylvania - Philadelphia

Texas

  • MD Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 21 participants
Start Date 2023-11-06
Est. Completion 2040-01-03
Phase Phase 1
Janssen Research & Development

593 total trials

What the registry record for NCT05784441 still lists

NCT05784441 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 27-participant average among 3 other Relapsed or Refractory B Cell Non-Hodgkin Lymphoma trials with a reported enrollment target (22% lower).

The record links to 1 condition, with Relapsed or Refractory B Cell Non-Hodgkin Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which JNJ-90009530 is the first listed.

NCT05784441 lists 15 locations in 8 states (Other, Iowa, Kentucky).

Frequently Asked Questions

What is clinical trial NCT05784441 about?

NCT05784441 is a clinical study titled "A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL)". The goal of this multicenter study is to test JNJ-90009530 in Relapsed or Refractory Non-Hodgkin Lymphoma Patients. The main questions the study aims to answer are: * can a dose of JNJ-90009530 be determined that is safe and well tolerated by patients. * will JNJ-90009530 help patients achieve a re...

What is the current status of trial NCT05784441?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2023-11-06. Estimated completion is 2040-01-03.

What conditions does trial NCT05784441 study?

This clinical trial studies the following conditions: Relapsed or Refractory B Cell Non-Hodgkin Lymphoma.

What interventions are being tested in trial NCT05784441?

The interventions under investigation include: JNJ-90009530 (DRUG).

Who is sponsoring clinical trial NCT05784441?

This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05784441 being conducted?

This trial has 15 study locations across Iowa, Kentucky, Minnesota, New Jersey, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Relapsed or Refractory B Cell Non-Hodgkin Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02447874 · 21 participants · Phase 1

    Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease

  • NCT03826992 · 21 participants · Phase 1

    Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia

  • NCT04107077 · 21 participants · Phase 2

    Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer

  • NCT04158635 · 21 participants · Phase 1

    Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT05784441, the US trial registry maintained by the National Library of Medicine. NCT05784441 (small enrollment · multi site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.